Ke huhū nei ʻo SARS-CoV-2 (COVID19) a puni ka honua, a ua ʻike ʻia ka lāʻau lapaʻau ʻo ia ke ala ʻoi aku ka maikaʻi a me ka maikaʻi e pale ai i ka maʻi maʻi maʻi.Hoʻohana ka loiloi kuʻuna maʻamau i nā ʻano hana ʻike antibody no ka loiloi i ka pono o nā kano ma o nā hoʻokolohua neutralization;
ʻO nā hana kuʻuna i ka manawa a me ka haʻahaʻa i ka pono, e lawe mau ana i ka 2 a 4 mau lā e hoʻopau ai i ka loiloi, a no ka hoʻohana ʻana o ka hapa nui o lākou i nā maʻi maʻi ola, pono ia e lawe ʻia ma kahi biosafety pae 3 a i luna o ka hale hana, ʻo ia ka manawa- hoʻopau a hana, a lawe mai i ka pilikia nui i ka loiloi o ka hoʻonui a me ka hōʻuluʻulu.No laila, he koi koʻikoʻi no kahi ala maʻalahi a wikiwiki hoʻi i kūpono no ka loiloi ʻana i nā antibodies pale i nā heluna nui.
Hoʻohana ʻia ʻo Aehealth COVID19 Neutralization Antibody Quantitative Test Kit no ka ʻike nui ʻana o ka COVID19 neutralizing antibodies i ka serum kanaka, plasma a i ʻole ke koko holoʻokoʻa.Hiki ke hoʻohana ʻia no ka ʻike wikiwiki, quantitative a koʻikoʻi loa i ka vitro.hoʻohana maʻi i ka loiloi kōkua o ka hopena o ke kano coronavirus hou a me ka loiloi o ka neutralizing antibodies i nā maʻi i hoʻōla ʻia ma hope o ka maʻi.
Hoʻopau maikaʻi ka neutralizing antibodies i ka maʻi ma o ka pale ʻana i ka pilina ma waena o ka maʻi COVID19 a me nā pūnaewele hoʻokipa.ʻO ka hapa nui o nā antibodies neutralizing e pane i ka receptor binding domain (RBD) o ka spike protein, e hoʻopili pololei ana i ka cell surface receptor ACE2.Ke hāʻawi nei nā antibodies-online i ʻelua neutralizing antibodies e pili ana i ka clone CR3022.ʻOiai ʻo ka hapa nui o nā antibodies S-protein RBD hoʻopaʻa i ka antigen paʻa me ACE2, ʻaʻole e uhi ka epitope CR3022 me ka pūnaewele paʻa ACE2.
No laila ʻaʻole ia e pale i ka hoʻopaʻa ʻana i nā antibodies neutralizing.ʻOiai ʻo CR3022 ma kāna iho hōʻike wale i kahi hopena neutralizing nāwaliwali, ua hōʻike ʻia e synergize me nā antibodies paʻa S-protein RBD e hoʻopau i ka COVID19.
Hana maʻalahi
- ʻAʻole pono e aʻo ʻia nā ʻoihana;
- Haʻahaʻa hāpana noi, pono wale 50 μL;
- Hoʻohālikelike me nā ʻano specimen he nui: Serum/Plasma/Whole blood.
ʻIke kiʻekiʻe
- Manaʻo: 98.95%;
- Mea kiko'ī: 100%.
Pono
- Manawa pane: 15 mins, Manawa hoao: 10s;
- Protable, Nā hiʻohiʻona hoʻohana ākea;
- ʻO ka pākaukau i kūkulu ʻia, ʻoi aku ma mua o 200 mau hoʻāʻo me ka ʻole o ka mana.
hilinaʻi
- Ua hōʻoia ʻia e 3600 hoʻokolohua lapaʻau, 1500 hoʻāʻo e ka mea maʻi maʻi specimen, 900 hoʻāʻo ma nā lāʻau lapaʻau, 1200 hoʻokolohua e ka poʻe maʻamau.;
- Loaʻa ka ʻikepili lapaʻau mai ka poʻe lapaʻau ma o ka lāʻau lapaʻau inactivated, nucleic acid vaccine, protein vaccine, a me nā maʻi maʻi maʻi, nā kānaka maʻamau.
- ʻOki i ka helu inhibition waiwai o 30%.
ʻO ke kumu kumu i hoʻohana ʻia i loko o kēia kit ʻo ia ka hoʻokūkū immunochromatographic. ʻO ka laina ʻike (T-line) ma ka ʻāpana hoʻāʻo ua uhi ʻia me ka angiotensin converting enzyme 2 a ua uhi ʻia ka laina mana (C-line) me ka anti-rabbit IgG antibody. Ua uhi ʻia ka pad conjugate me ka protein COVID19 RBD i kapa ʻia i ka flfluorescently a me ka flfluorescently labeled rabbit IgG antibody.I ka wā o ka ʻike ʻana, inā loaʻa i ka hāpana ka antibody e hoʻāʻo ʻia, ʻo ka conjugate o ka mea hoʻāʻo i loko o ka laʻana a me ka flfluorescent antigen e hana i kahi paʻakikī paʻakikī a ʻaʻole hiki ke hoʻopaʻa hou ka paʻakikī i ka angiotensin-converting enzyme 2 immobilized ma ka membrane nitrocellulose. .ʻO ka conjugate antigen flfluorescent ʻaʻole i hoʻopaʻa ʻia i ka antibody e hoʻāʻo ʻia e hoʻopaʻa i ka angiotensin hoʻololi i ka enzyme 2 i hoʻopaʻa ʻia ma ka membrane nitrocellulose e hana i kahi laina ʻike (T).
- Ka hoʻāʻo ʻana ma mua o ka hoʻopaʻa ʻana;
- Ka nānā 'ana i nā hopena ma hope o ka lā'au lapa'au;
- ʻO ka loiloi pilikia no ka maʻi lua o ka poʻe i maʻi ʻia;
- Ka loiloi pilikia no nā kānaka maʻamau (me ka maʻi asymptomatic) hiki ke loaʻa i ka maʻi;
- ʻO ka hoʻāʻo ʻana i ka hiki ke kū i ka maʻi virus.